Perrigo Company plc

NYSE:PRGO

Drug Manufacturers - Specialty & Generic

Healthcare
$16.94 -1.97%

-$0.20 today

Market cap
$2.35B
Beta
0.52
P/E (TTM)
-0.8
EPS (TTM)
-$13.10
Dividend yield
11.65%
52W Low $9.23High $28.44

Volume 2.57M

Average 2.96M

PRGO Operating Cash Flow

Cash generated by the company's core business operations during the period.

Perrigo Company plcNYSE: PRGO

Operating Cash Flow · Q2 FY2026 · quarter ended Jun 2026

Operating cash flow growth accelerates

Q2 FY2026 operating cash flow of $138.3M rose 82.2% year over year, ahead of the -31.2% change in trailing-twelve-month operating cash flow. Over 3 fiscal years it compounded at -8.1% a year.

Context

  • Operating cash flow amounted to 5.6% of revenue in FY2025, down 2.7 pp from a year earlier.
  • Operating cash flow increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +82.2% holds above the trailing-twelve-month pace of -31.2%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$138.3M+221.7% QoQ
Last fiscal yearDec 2025
$238.5M-34.3% YoY
LTMJun 2026
$251.8M-31.2% YoY
Operating Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+82.2%——
1 year-34.3%——
3-year CAGR-8.1%——
5-year CAGR——
10-year CAGR——

Operating Cash Flow history

USD · from the cash flow

Latest · FY2025
238.5M USD
Year-over-year change
-34.3%
4-year CAGR
+11.1%

Operating Cash Flow vs competitors

How PRGO compares with its peers on the latest reported figures

  • PRGO's LTM Jun 2026 operating cash flow of $251.8M is the 4th largest of the 10 companies compared; the peer median is $49.9M.
  • Its year-over-year change of -31.2% is the 9th highest of 10, against a peer median of -1.6%.
  • Operating cash flow amounts to 6.1% of revenue for PRGO, versus a peer median of 8.3%.
PRGO Competitors Peer median
Operating Cash Flow for PRGO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BHCBausch Health Companies Inc.LTM Jun 2026$1.8B +19.7%—16.6%
SRRKScholar Rock Holding CorporationLTM Sep 2026$309.05M +12.8%+31.3%54218.6%
SGRYSurgery Partners, Inc.LTM Sep 2026$277.9M -1.6%+20.0%8.3%
PRGOPerrigo Company plcLTM Jun 2026$251.8M -31.2%-8.1%6.1%
LIVNLivaNova PLCLTM Sep 2026$237.8M -5.1%+53.8%15.8%
ATECAlphatec Holdings, Inc.LTM Mar 2026$51.56M +558.2%—6.6%
TARSTarsus Pharmaceuticals, Inc.LTM Sep 2026$49.9M +192.5%-36.7%7.3%
HTFLHeartflow, Inc. Common StockLTM Sep 2026$48.95M -14.8%—20.5%
HCMHUTCHMED (China) LimitedLTM Jun 2025$32.57M -30.7%-37.7%5.4%
SUPNSupernus Pharmaceuticals, Inc.LTM Jun 2026$19.91M -89.4%-26.0%2.4%
Peer median (excluding PRGO) $49.9M-1.6%-3.0%8.3%

Competitors are the stored peer set for PRGO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(68.9M)(130.9M)(12.7M)(171.8M)(1.4B)
Depreciation & Amortization312.2M338.6M359.5M325.9M337.5M
Deferred Income Tax9.4M(50.5M)(106.6M)9.8M(50.8M)
Stock-Based Compensation60.1M068.8M64.4M0
Change in Working Capital(295.4M)20M(58.5M)(74.7M)(101.1M)
Accounts Receivables(159.7M)100K(57.1M)(11.1M)30.7M
Inventory(2.4M)(76.7M)19.4M13.7M(61.1M)
Accounts Payables(7.9M)100.3M(65.9M)54.2M(28.7M)
Other Working Capital(125.4M)(3.7M)45.1M(131.5M)(42M)
Other Non-Cash Items138.9M130.1M155M209.3M1.46B
Operating Cash Flow156.3M307.3M405.5M362.9M238.5M
Capital Expenditures(152.1M)(96.4M)(101.7M)(118.3M)(93.4M)
Acquisitions (Net)1.49B(1.95B)000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities(64M)90.5M24.2M197.1M18M
Investing Cash Flow1.28B(1.96B)(77.5M)78.8M(75.4M)
Debt Repayment(30.6M)583.6M(30.2M)(437.8M)(34.8M)
Common Stock Issued00000
Common Stock Repurchased00000
Dividends Paid(129.6M)(142.4M)(149.7M)(152.5M)(159.3M)
Other Financing Activities(18.5M)(19.6M)(7.3M)(20.7M)(26.4M)
Financing Cash Flow(178.7M)421.6M(187.2M)(611M)(220.5M)
Effect of Forex Changes(15.6M)(34.5M)9.8M(23.2M)30.2M
Net Change in Cash1.23B(1.26B)150.6M(192.5M)(27.2M)
Free Cash Flow4.2M210.9M303.8M244.6M145.1M

Perrigo Company plc

NYSE:PRGO

Intrinsic Alpha fair value

Locked

Current Price

$16.94

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.